27 October 2025 in Clinical Pharmacology & Therapeutics
TCthe Pharmacogenomics Global Research Network (PGRN) Publications Committee
the Pharmacogenomics Global Research Network (PGRN) Publications Committee
+3
Pharmacovigilance is a critical component of medication safety. Despite rigorous evaluation of new drugs during clinical trials, some adverse effects might only be identified once pharmaceuticals are used by a larger population for a longer duration. Adverse drug reactions cause negative healthcare outcomes and in severe cases, may lead to hospital admissions, delayed hospital discharges, or deaths. Adverse event reports submitted to pharmacovigilance programs by healthcare professionals and consumers are a key source of information regarding previously unrecognized detrimental effects. Pharmacogenetic markers that indicate how particular genes impact an individual’s response to medication can help explain some idiosyncratic adverse reactions. Incorporating pharmacogenomic guidance in prescribing is proven to decrease the incidence of adverse reactions and improve clinical outcomes. However, this information is not yet routinely included in incident reports. In this era of precision medicine, when prescribing can be tailored to the individual, pharmacogenomic test results yield valuable data that can enhance both individual and population health. Furthermore, advanced artificial intelligence (AI) and machine learning (ML) methods facilitate analysis of complex genetic data, revealing insights not previously available. This white paper outlines current pharmacovigilance and pharmacogenomic practices and recommends that pharmacovigilance programs include pharmacogenomics as a crucial data point in their investigations.
8 January 2026 in medRxiv
Angioedema is a life-threatening adverse drug reaction associated with renin-angiotensin-aldosterone system (RAAS) inhibitors, characterized by localized swelling in the deep layers of the skin. Well-established evidence indicates an up to fivefold higher incidence of RAAS inhibitor-induced angioedema in self-identified Black patients compared to White patients. The mechanisms underlying this health disparity remain poorly understood and are often attributed to race, a poor proxy for interindividual genetic similarity and social stressors. Here, we investigate the genetic and social determinants of RAAS inhibitor-induced angioedema as well as the etiology of this racial difference. In particular, we (1) discovered OTULINL and CRABP1 as novel loci for RAAS inhibitor-induced angioedema, (2) confirmed the importance of bradykinin for this adverse drug reaction, (3) reported the first significant genome-wide association in self-identified Black participants, (4) identified alcohol use as an important social determinant, (5) demonstrated the strong role of variants enriched in 1000 Genomes African superpopulation-like genomes as the driver of racially differential angioedema risk, and (6) demonstrated the combined role of polygenic effect size and allele frequency differences in explaining these racial differences. Our results suggest that a clinical precision medicine tool may more precisely predict for whom RAAS inhibitors should be avoided (to prevent angioedema) compared to using race. These findings ultimately underscore the value of an evidence-based approach to removing race from treatment guidelines, which carries less potential harm than other removal strategies.